2008•Leukemia & lymphoma/Leukemia and lymphomaRequires access
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL
Alison Morilla, David González de Castro, Ilaria Del Giudice, Nnenna Osuji, Monica Else, Ricardo Morilla, Vasantha Brito Babapulle, Hannah C. Rudenko, Estella Matutes, Claire Dearden, Daniel Catovsky, Gareth J. Morgan
Open publisher page 53 citations
Abstract
ZAP-70, CD38 and IGHV mutations have all been reported to have prognostic impact in chronic lymphocytic leukemia (CLL), both individually and in paired combinations. We aimed to determine whether the combination of all three factors provided more refined prognostic information concerning the treatment-free interval (TFI) from diagnosis. ZAP-70, CD38 and IGHV mutations were evaluated in 142 patients. Combining all three factors, the ZAP-70-/CD38-/Mutated group showed the longest median TFI (62 months, n = 37), ZAP-70+/CD38+/Unmutated cases the shortest (11 months, n = 37) and cases discordant for > or = 1 factor, an intermediate TFI (27 months, n = 68) (p = 0.006). Analysis of discordant cases revealed values that were otherwise masked when measuring single prognostic factors. The presence or absence of cytogenetic abnormalities did not explain the variability among discordant cases. Simultaneous analysis of ZAP-70, CD38 and IGHV mutations in CLL provides more discriminatory prediction of TFI than any factor alone.